Shares in Sun Pharma fell a huge 6 per cent, after the company said that it had received a warning letter for its Halol Plant from the US FDA.
The shares were last trading at Rs 737, down almost 6 per cent over Friday's close. Commenting on the development, Dilip Shanghvi, Managing Director, Sun Pharma said, "While our team is working hard to ensure that the commitments made to the US FDA in September 2014 are fully completed, we will continue to cooperate with the US FDA and undertake any additional steps necessary to ensure that the US Agency is completely satisfied with our remediation of the Halol facility.
Sun Pharma has always ensured that its products are safe and effective and there is no doubt on the safety of our products in the market. We are pledged to being cGMP compliant and are committed to continuing to supply our customers and patients across the world with quality products that meet all specifications."
For investment related articles, business news and mutual fund advise, subscribe to GoodReturns.